Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009011 | 1.00 | MAPK1 (0.53) | MAPK1SLC18A3ADAMTS5CYP2D6GSK3B | |
| SCHEMBL20009034 | 1.00 | MAPK1 (0.53) | MAPK1SLC18A3ADAMTS5CYP2D6GSK3B | |
| SCHEMBL19003704 | 0.85 | MAPT (0.43) | MAPK1GSK3BHRH3MAPTNPSR1 | |
| SCHEMBL27157534 | 0.83 | HRH3 (0.41) | MAPK1SLC18A3ADAMTS5GSK3BHRH3 | |
| SCHEMBL27204206 | 0.83 | HRH3 (0.41) | MAPK1SLC18A3ADAMTS5GSK3BHRH3 | |
| SCHEMBL17897284 | 0.83 | ADAMTS5 (0.43) | MAPK1SLC18A3ADAMTS5CYP2D6GSK3B | |
| SCHEMBL17897270 | 0.83 | ADAMTS5 (0.43) | MAPK1SLC18A3ADAMTS5CYP2D6GSK3B | |
| SCHEMBL19003576 | 0.83 | ADAMTS5 (0.43) | MAPK1SLC18A3ADAMTS5CYP2D6GSK3B | |
| SCHEMBL26239828 | 0.81 | CYP2D6 (0.39) | MAPK1SLC18A3CYP2D6HRH3MAPT | |
| SCHEMBL13899013 | 0.81 | KDM4E (0.44) | MAPK1GSK3BHRH3TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | MAPK1 1770/4885SLC18A3 3291/4885ADAMTS5 4424/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | MAPK1 1770/4885SLC18A3 3291/4885ADAMTS5 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.